Skip to content
MARKETS / NASDAQ / COCP
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Cocrystal Pharma, Inc. COCP

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$-8.8M
$-8.2M
In brief

What this company does

The Company operates as one business entity. We are developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses causing acute and chronic viral diseases. To discover and design these direct-acting antiviral drug candidates, we use a proprietary platform comprising computational chemistry, medicinal chemistry, X-ray crystallography and our extensive know-how. We developed our proprietary structure-based drug design under the guidance of Dr. Roger Kornberg, our Chief Scientist and Chairman of both our Scientific Advisory Board (“SAB”) and Board of Directors (the “Board”), who received the Nobel Prize in Chemistry in 2006.

Written from the business description in Cocrystal Pharma, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2020 · Revenue 2.0 · Net income -9.6
5M10M-20M-40M201020122014201620182020202220242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
Operating margin Net margin
FY2020 · Operating -476.0% · Net -479.0%
-200%-400%-600%201020122014201620182020202220242025
ROE
FY2025 · ROE -111.4%
-50%-100%201020122014201620182020202220242025

Each USD of equity lost 111 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -8.2
-8M-16M201020122014201620182020202220242025

Total assetsUSD 9.7M
EquityUSD 6.3M
CashUSD 7.0M
Current ratio3.68×

Equity funds 65% of total assets.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B·····0.00.0·······0.0·
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.0−0.1−0.1−0.0−0.0−0.0−0.0−0.0
EBITDA $B·······−0.1−0.0−0.1−0.1−0.0−0.0···
Income tax $B·······−0.0−0.0−0.0−0.0−0.0··0.0−0.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.1−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.78−1.72−1.87−4.77−0.16−0.17−1.51−1.75−0.03−3.30−2.40−0.01−0.07·−0.11·
Dividend / sh $················
Payout %················
ROE %−111.4−97.5−54.5−66.3−21.8−24.7−104.0−56.9−0.6−55.5−57.5·····
Shares out B0.010.010.010.010.010.070.040.030.020.020.690.000.000.060.060.04

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 1 failures · 1 divergences in 63 reconciliationsAUDITED

Reconciled in 14 of 19 fiscal years. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 32 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente1 failures1 divergent
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image